Literature DB >> 19184202

Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer.

Kentaro Inoue1, Yasushi Nakane, Taku Michiura, Sou Yamaki, Rintaro Yui, Kazuhito Sakuramoto, Aiko Iwai, Katsuji Tokuhara, Yoshiro Araki, Songtae Kim, Koji Nakai, Mutsuya Sato, Keigo Yamamichi, A-Hon Kwon.   

Abstract

BACKGROUND: A better method for detecting early peritoneal progression is needed. This study evaluated the feasibility and accuracy of second-look laparoscopy for patients with gastric cancer treated using systemic chemotherapy after gastrectomy.
METHODS: Second-look laparoscopy was conducted for patients who had no clinical evidence of distant metastases but had peritoneal metastases or positive peritoneal cytology results without visible metastatic disease at initial surgery, patients who underwent systemic chemotherapy over a 6-month period after surgery, and patients who had no clinical evidence of disease based on imaging study after completion of primary chemotherapy.
RESULTS: Between November 2004 and April 2008, 21 patients underwent second-look laparoscopy. At the initial surgery, 13 of these patients underwent total gastrectomy and 8 patients underwent distal gastrectomy. One or two sheets of adhesion barrier were received by 18 patients. The median interval between initial surgery and second-look laparoscopy was 9.8 months (range, 6.6-17.5 months). All second-look procedures were completed laparoscopically, and no patients required conversion to laparotomy. None of the 21 patients experienced postlaparoscopy complications. Whereas 12 patients showed no pathologic evidence of disease, 9 patients showed disease at second-look laparoscopy. There was a significant difference in median survival between the groups with negative and positive results (p = 0.017). The median survival for the negative group has not been determined. All the patients in the positive group received further chemotherapy while showing a good performance status (PS). Six patients were PS 0, and 3 patients were PS 1. The median survival time for this group was 10.1 months.
CONCLUSIONS: Second-look laparoscopy was a safe and promising approach to reassessment of peritoneal disease for patients with gastric cancer. The incidence of complications was low, particularly in this group of patients, all of whom had undergone prior gastrectomy.

Entities:  

Mesh:

Year:  2009        PMID: 19184202     DOI: 10.1007/s00464-008-0324-z

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  34 in total

1.  Peritoneoscopy: a valuable staging tool in ovarian carcinoma.

Authors:  S H Rosenoff; R C Young; T Anderson; C Bagley; B Chabner; P S Schein; S Hubbard; V T DeVita
Journal:  Ann Intern Med       Date:  1975-07       Impact factor: 25.391

2.  The use of laparoscopy to determine the results of chemotherapy for ovarian cancer.

Authors:  W G Smith; T G Day; J P Smith
Journal:  J Reprod Med       Date:  1977-05       Impact factor: 0.142

3.  Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma.

Authors:  Abeezar I Sarela; Thomas J Miner; Martin S Karpeh; Daniel G Coit; David P Jaques; Murray F Brennan
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?

Authors:  Evangelos Briasoulis; Michael Fatouros; Dimitrios H Roukos
Journal:  Ann Surg Oncol       Date:  2007-07-26       Impact factor: 5.344

5.  Improvement in treatment results of gastric cancer with surgery and chemotherapy: experience of 9,700 cases in the Cancer Institute Hospital, Tokyo.

Authors:  T Nakajima; M Nishi; T Kajitani
Journal:  Semin Surg Oncol       Date:  1991 Nov-Dec

6.  Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.

Authors:  A Gadducci; E Sartori; T Maggino; P Zola; F Landoni; A Fanucchi; N Palai; C Alessi; A M Ferrero; S Cosio; R Cristofani
Journal:  Gynecol Oncol       Date:  1998-02       Impact factor: 5.482

7.  Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.

Authors:  J A Ajani; P F Mansfield; P M Lynch; P W Pisters; B Feig; P Dumas; D B Evans; I Raijman; K Hargraves; S Curley; D M Ota
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

8.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

9.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Authors:  Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

10.  Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.

Authors:  Sang Joon Shin; Hei-Cheul Jeung; Joong Bae Ahn; Hye Jin Choi; Byoung Chul Cho; Sun Young Rha; Nae Choon Yoo; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-11       Impact factor: 3.333

View more
  2 in total

1.  Monitoring and assessing the intraabdominal therapeutic response for gastric cancer: is second-look laparoscopy the solution?

Authors:  Odysseas Zoras; John Spiliotis
Journal:  Surg Endosc       Date:  2010-09       Impact factor: 4.584

2.  Follow-up after curative resection for gastric cancer: Is it time to tailor it?

Authors:  Paolo Aurello; Niccolò Petrucciani; Laura Antolino; Diego Giulitti; Francesco D'Angelo; Giovanni Ramacciato
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.